|Bid||11.76 x 0|
|Ask||12.50 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
WOONSOCKET, RI and TORONTO, May 10, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced further growth in the distribution and availability of their line of CBDMEDIC™ products. "These purchase orders, which range from six to twelve unique SKUs across our pain relief and therapeutic skincare lines, demonstrate the continued strong interest by retail chains to bring CBDMEDIC™ products onto their shelves," said Perry Antelman , CEO of Abacus. Further, a 2018 research report by Allied Market Research estimated the global topical pain relief market to be approximately US$7.4 billion in 2017.
WOONSOCKET, RI , April 17, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced the hiring of two new members to its senior management team. James Barkat has been named Vice President of Marketing for Abacus. Prior to joining the Company, Mr. Barkat spent over ten years at Sanofi Consumer Health, where he most recently served as U.S. Marketing Head – Digestive Health, a $300 million portfolio that includes brands such as Dulcolax, Zantac, and Rolaids.
Each Unit will be comprised of one subordinate voting share of the Company (a “Subordinate Voting Share”) and one-half of one Subordinate Voting Share purchase warrant (each whole warrant, a “Warrant”).
The Company has agreed to grant the Underwriters an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional approximately $2,250,150 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be approximately $17,251,150.
WOONSOCKET, RI , April 11, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced the latest round of purchase orders for their line of CBDMEDIC™ products. "These new purchase orders demonstrate strong momentum and the successful execution of our retail growth strategy," said Perry Antelman , CEO of Abacus.
Abacus Health Products (OTCMKTS:ABAHF) has launched 10 over-the-counter pain relief products. The CBDMEDIC pain-relief line is designed to treat different types of pain. Helping Millions of Americans in Pain The CBDMEDIC pain-relief line offers solutions for sports-related joint and muscle pain, back and neck pain, arthritis-related pain, stiffness and swelling, and muscle and joint pain. […]The post Abacus Health Launches CBDMEDIC Pain Relief Medications appeared first on Market Exclusive.
After two years of distributing topical pain relief products to the clinician market, the Company introduces its over-the-counter line for consumers, available nationwide WOONSOCKET, R.I. , March 27, 2019 ...
POINT ROBERTS, Wash. and DELTA, British Columbia, March 14, 2019 -- We are advised by InvestorIdeas.com that journalists and other readers should disregard the news release,.
POINT ROBERTS, Wash. and DELTA, British Columbia, March 14, 2019 -- Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a snapshot.
Ontario-incorporated Abacus Health Products, Inc. , previously World Wide Inc., has completed its merger with Delaware-incorporated Abacus Health Products, Inc.